NYSE · NUVB
Nuvation Bio Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NUVB: Nov 04, 2026
Nuvation Bio Inc. Class A Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.12. The reported EPS for the same quarter last year was $-0.16.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.12 | $-0.09 | $-0.15 | 5 |
| Dec 2026 | $-0.10 | $-0.09 | $-0.12 | 5 |
| Mar 2027 | $0.00 | $0.01 | $0.00 | 3 |
| Jun 2027 | $-0.06 | $-0.05 | $-0.06 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · BNK Invest · Zacks- RTTNews · Oct 29, 2:28 PM EDTNuvation Bio Advances Phase 3 Trial Of Safusidenib As Maintenance Therapy For Glioma(RTTNews) – Nuvation Bio Inc. (NUVB) announced that its pivotal Phase 3 SIGMA study of investigational safusidenib for IDH1-mutant glioma will expand to include clinical trial sites in the United Kingdom, France, Sweden, Germany, Italy and Spain.
- Fintel · Sep 30, 4:30 PM EDTCitigroup Initiates Coverage of Nuvation Bio with BuyFintel reports that on September 30, 2026, Citigroup initiated coverage of Nuvation Bio (NYSE:NUVB) (DB:1E30) with a Buy recommendation.This initiation follows a period where Nuvation Bio's stock closed at $5.62 on September 29, 2026. Over the short term, the company's share pric
- RTTNews · Sep 18, 10:44 AM EDTWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) – Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
- BNK Invest · Sep 17, 4:23 PM EDTNUVB Makes Bullish Cross Above Critical Moving AverageIn trading on Thursday, shares of Nuvation Bio Inc (Symbol: NUVB) crossed above their 200 day moving average of $5.92, changing hands as high as $6.16 per share. Nuvation Bio Inc shares are currently trading up about 5.6% on the day. The chart below shows the one year performa
- RTTNews · Sep 17, 9:02 AM EDTNuvation Bio Wins FDA Nod For Updated IBTROZI Label Showing 50-Month DOR In ROS1+ Lung Cancer(RTTNews) – Nuvation Bio Inc. (NUVB), announced that the U.S. FDA has approved a sNDA for IBTROZI, updating the drug's label to include new long-term efficacy data for treatment-naïve patients with advanced ROS1+ NSCLC.
- Zacks · Sep 3, 9:55 AM EDTDoes Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Aug 31, 12:00 PM EDTNuvation Bio (NUVB) Upgraded to Buy: Here's WhyNuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Aug 21, 3:44 AM EDTNuvation Bio Secures FDA Fast Track For Safusidenib In IDH1- Mutant Glioma(RTTNews) – Nuvation Bio Inc. (NUVB) announced that the U.S. FDA has granted Fast Track Designation to Safusidenib, its investigational oral therapy targeting IDH1- mutant glioma.
- Zacks · Aug 18, 9:55 AM EDTWall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should KnowThe mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- The Motley Fool · Aug 13, 12:30 PM EDTNuvation Bio (NUVB) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 8, 5:03 PM EDTNuvation Bio Q2 Earnings Call HighlightsNuvation Bio (NYSE:NUVB) reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, as the company said use of the ROS1-targeted lung cancer therapy continued to shift toward first-line patients. IBTROZI revenue incr
- Zacks · Aug 6, 9:50 AM EDTNuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue EstimatesNuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +16.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Nuvation Bio Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.